Mesoblast (MESO) reported H1 FY2026 total revenue of USD 51.3 million, up from USD 3.2 million, driven by the U.S. commercial launch of Ryoncil. The company said Ryoncil generated gross sales of USD 57.0 million and revenue of USD 48.7 million after gross-to-net adjustment, with gross profit (excluding amortization) of USD 44.2 million and direct selling costs of USD 7.7 million. Net loss attributable to shareholders was USD 40.2 million, versus USD 47.9 million a year earlier, and net operating cash spend was USD 30.3 million; cash and cash equivalents were USD 130.0 million at Dec. 31, 2025. Operationally, Mesoblast said 49 transplant centers have been onboarded toward a target of 64, and payer coverage extends to 280 million U.S. lives; it also cited “real-world” data showing 84% of patients completed the initial 28-day treatment regimen per label and were alive. The company said the Phase 3 protocol for adult steroid-refractory acute graft-versus-host disease is locked following an FDA meeting and will be submitted to an IRB in March for site initiation. Mesoblast reiterated FY2026 Ryoncil net revenue guidance of USD 110 million to USD 120 million and said it entered into a USD 125.0 million five-year non-dilutive credit-line facility, with a second tranche of USD 50.0 million available to draw until June 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602261942PRIMZONEFULLFEED9662644) on February 27, 2026, and is solely responsible for the information contained therein.